secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001493152-24-006132
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio reduces board from 8 to 4; four directors resign, Chairman changed
-------------------------------------------------------------------------------

- Directors James Neal, Stephanie Diaz, Cristina Csimma, Robert Trenschel resigned immediately; no disagreement cited.
- Board cut from 8 to 4 members; Donald Williams appointed Chairman.
- Recent warrant exercise generated $2.5 million gross proceeds.
- PALI-2108 Phase 1 study on track to start before end of 2024; IND/CTA submission planned by year end.
- Positive preclinical data presented at 2024 Crohn's & Colitis Congress; second milestone payment received from IBD Ventures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000149315224006132/0001493152-24-006132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000149315224006132/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-006132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer